Lumanity is proud to be taking part at ISPOR Europe 2022, the leading health economics and outcomes research (HEOR) conference. ISPOR brings together global HEOR leaders, policy makers, regulators, researchers, academics, payers, patients, and patient groups under one roof to network and discuss and debate this year’s topic ‘Collaborating Across Borders: Building & Using Evidence to Enable Access’.

Join us at ISPOR to hear from our many experts who will be presenting workshops, posters and presentations at the conference – you can find full details of these sessions below. Lumanity will also have an exhibit booth in Hall 3 of the exhibition, where you will be able to meet our experts in person, discuss your upcoming projects needs with our team, and meet with our talent specialists to find out about the many exciting opportunities to join us and develop your career at Lumanity.

Our sessions

Short Course

Sunday, 6 November
08:00 – 12:00 am (CET) | In-person

Health Economic Modeling in R: A Hands-on Introduction

In this hands-on introductory workshop, Lumanity’s Rose Hart joins Gianluca Baio, University College London, Felicity Lamrock, Queens University Belfast, and Howard Thom, University of Bristol, to explore the use of R for health economic modelling in the context of health economics and outcomes research (HEOR).

Workshops

Monday, 7 November
13:30 – 14:30 pm (CET) | In-person


W6 | Technical Support Document (TSD) 20 in Action — What to Consider When Using Multivariate Meta- or Network Meta-Analyses (NMA) to Support HTA Oncology Submission.

Lumanity’s Miranda Cooper joins the discussion on multivariate meta-analysis (MA) or NMA methods outlined in NICE TSD 20 and how they can be used to cohesively analyse the relative efficacy of a treatment for two or more correlated endpoints.


Tuesday, 8 November
13:30 – 14:30 pm (CET) | Virtual

Advanced Forecasting: Incorporating External Data within Survival Extrapolations

A discussion on new methods of using external data to improve survival extrapolations, using case studies as examples.

HEOR Theatre

Monday, 7 November
14:45 – 15:15 pm (CET) | In-person

EU Joint Clinical Assessments: What Happens When Gold-Standard Evidence is Out of Reach?

In this HEOR theatre, our experts explore Regulation (EU) 2021/2282, published in December 2021, which aims to harmonize health technology assessment (HTA) across the European Union by launching the EU-wide Joint Clinical Assessment (JCA).

Our experts will discuss what changes and challenges this new regulation may bring to manufactures developing health technology assessments, particularly for innovative technologies and rare diseases.

Issue Panel

Tuesday, 8 November
16:30 – 17:30pm (CET) | In-person

Moderator: Ron Akehurst.
Panelists: Jill Carlton, Fleur Chandler, Peter I Neumann.

Treating the Family and Not the Individual- How Can We Capture Burden and Quality of Life for Familial Carers of Those with Life Limiting Illness?

The panel will discuss whether there is any case to include wider carer considerations in HTA and, if they are included, the appropriate ways in which it might be done. Lumanity’s Ron Akehurst, will moderate the session and pose questions to the panel.

Posters

Monday, 7 November
10:00 – 13:15 am (CET) In-person

Bowditch S, Burke C, Crossan C, Hemstock M, Tyas E, Lee D

Cost-Effectiveness of Cannabidiol Add-on Therapy Versus Placebo for the Treatment of Seizures in Tuberous Sclerosis Complex 


Monday, 7 November
10:00 – 13:15 am (CET) In-person

Smith M, Matthijsse S.

Evolving Landscapes for Advanced Therapy Medicinal Products (ATMPS): Access in the US, UK & EU


Monday, 7 November
15.00 18.15 pm (CET) In-person

Verma R, Mittal R, Mazhar M, Ahuja A.

Economic Burden of Malignant Pleural Mesothelioma in Europe: A Systematic Literature Review


Monday, 7 November
15.00 18.15 pm (CET) Virtual

Butler J, Theodore-Oklota C, Egan S, Evans C.

Development of Conceptual Frameworks and Patient-Reported Outcome Measures in Glycogen Storage Disease Type Ia (GSDIa)


Monday, 7 November
15.00 18.15 pm (CET) In-person

Dress A, Butler J, Theodore-Oklota C, Egan S, Evans C.

Development of Conceptual Frameworks and PRO Measures in Ornithine Transcarbamylase Deficiency


Tuesday, 8 November
10.00 am 13.15 pm (CET) Virtual

Neves C, Kasle A, van Keep M, Matthijsse S.

Exploring the Effect of Different Patient Entry Intervals on Budget Impact Estimations


Tuesday, 8 November
10.00 am 13.15 pm (CET) In-person

Franklin M, Jones E, Shupo F, Mason N, Wayi-Wayi G, Zibelnik N, RepaskyM, Mukherjee S, Brazier JE.

Symptom Burden and Its Impact on Daily Living with Idiopathic Multicentric Castleman’s Disease: Development and Psychometric Validation of a Bespoke International Patient and Caregiver Survey


Tuesday, 8 November
15.00 18.15 pm (CET) In-person

Brook E, McNamara S, Hardern C, Metry A.

A Distributional Cost-Effectiveness Analysis of Screening Strategies for Ovarian Cancer


Tuesday, 8 November
15.00 18.15 pm (CET) In-person

Dress A, Theodore-Oklota C, Malkus B, Egan S, Umakanth S, Evans C.

Development of a Patient-Reported Outcome Measure in Wilson Disease


Tuesday, 8 November
15.00 18.15 pm (CET) In-person

Stergiopoulos S, King S, Curtis M, Dillon SA, Akehurst R, Lee D, Guelfucci F, Ngami A, Bianic F, Li Y, Ma X, Ali S, Miller VA, Popat S.

Indirect Comparison of Efficacy and Safety for Aumolertinib vs Osimertinib in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)


Tuesday, 8 November
15.00 18.15 pm (CET) Virtual

Filonenko A, Haberland C, Prosche A, Bolling KR, Gerlinger C, Britton J, Taneja A, Harchand S, Jindal S.

Work Productivity Loss Among Women with Menopausal Symptoms: A Systematic Literature Review


Tuesday, 8 November
15.00 18.15 pm (CET) In-person

Stevenson A, Stork R, Gaffney S, Haycroft B, Morgan P.

A Targeted Literature Review Exploring Surrogacy Relationships between Estimated Glomerular Filtration Rate (EGFR) and Left Ventricular Mass Index (LVMI) in Clinical Events in Fabry Disease


Tuesday, 8 November
15.00 18.15 pm (CET) In-person

Aguiar-Ibáñez R, Cagnan L, Bensimon L, Mamane C, Lebbink E, Crossan C, Tougeron D, De la Fouchardière C, Amonkar M.

Cost-Effectiveness of Pembrolizumab Monotherapy for First-Line Treatment in Adult Patients with Microsatellite Instability High/Mismatch Repair-Deficient Metastatic Colorectal Cancer from a French Perspective


Wednesday, 9 November
09:00 – 12:30 am (CET) | In-person

Madan T, Jindal S, Garg J, Saharia P.

Economic Evaluation of C5 Inhibitors in Patients with Paroxysmal Nocturnal Haemoglobinuria – Systematic Literature Review


Wednesday, 9 November
09:00 – 12:30 am (CET) | In-person

Nanda S, Jindal S, Rohilla A, Mahajan S, Saharia P.

Real World Evidence in Multiple Sclerosis (MS): HTA Decision-Making Influencer or Not?


Wednesday, 9 November
09:00 – 12:30 am (CET) | In-person

Mittal R, Aggarwal T, Verma R, Ahuja A.

A Systematic Literature Review (SLR) of Clinical Practice Guidelines (CPGS) and Real-World Treatment Patterns in Metastatic Gastrointestinal Stromal Tumours (MGISTS) in Europe


Wednesday, 9 November
09:00 – 12:30 am (CET) | In-person

Alulis-Nielsen S, Hassan F, Lee JM, Secchi O, Francesa Morel PC, Church E, Hart R.

The Optimized Patient Treatment Initiative (OPT-IN): Choosing the Right Therapy, for the Right Patient, at the Right Time


Wednesday, 9 November
09:00 – 12:30 am (CET) | Virtual

Azad M, Joshi H, Mittal R, Ahuja A.

Economic Burden of Patients with Glioblastoma in Key Five European Countries: A Systematic Review

Our Experts

At our ISPOR EU 2022 booth you will be able to speak to Lumanity experts from Health Economists, Statisticians, Strategic Leaders, Researchers to Recruiters.

Join Us

Lumanity are always on the lookout for creative thinkers, expert communicators, and data gurus to join our team. We believe investing in the career development, creating a safe and engaging environment and rewarding a job well done. If this sounds good to you, drop by our ISPOR EU 2022 booth, and talk to our team of talent specialists. You can also visit our careers page to find out what opportunities we are currently advertising.

LinkedIn

Follow us on LinkedIn to keep up to date on our ISPOR EU 2022 activities.

Contact us

"*" indicates required fields

This field is for validation purposes and should be left unchanged.